Slide 1: Glenmark Life Sciences cover letter to exchanges
8 qlenmaQk LIFE SCIENCES Partne rsh ip. In novat ion . Pass ion . October 21, 2022 To, To, Dy. General Manager The Manager – Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumb
Slide 2: Q2 FY23 Investor Presentation
Q2 FY23 Investor Presentation Glenmark Life Sciences Ltd G qlenma~k LIFE SCIENCES
Slide 3: Financial Performance Review
01 Financial Performance Review 2 G qlenma~k LIFE SCIENCES
Slide 4: Q2 FY23 – Highlights
Q2 FY23 – Highlights • Revenue grew by 4% on a QoQ and Revenue Dr. Yasir Rawjee decreased 4% over a higher base of Q2FY22 Managing Director & INR 5,093 mn (ex-covid) Chief Executive Officer • Gross Margins are at 52.9%, up 120 bps YoY “I am pleased to share that despite global uncertainties, the Com
Slide 5: P&L Highlights – Q2 FY23
P&L Highlights – Q2 FY23 Amounts in INR Millions Q2 FY23 Q1 FY23 QoQ Q2 FY22 YoY H1 FY23 H1 FY22 YoY Revenue from Operations 5,093.0 4,898.7 4.0% 5,617.6 -9.3% 9,991.7 10,866.6 -8.1% Gross Profit 2,693.1 2,609.7 3.2% 2,905.4 -7.3% 5,302.8 5,560.7 -4.6% Gross Profit (%) 52.9% 53.3% 51.7% 53.1% 51.2%
Slide 6: Key Balance Sheet Items and Cash flow
Key Key Balance Balance Sheet Sheet Items Items and and Cash Cash flow flow [ _ _] Key Balance Sheet Items [_ _ _] Free Cash Flow Amounts in INR Millions As at 30th As at 31st ------ Amounts in INR Millions H1 FY23 H1 FY22 Sep'22 Mar'22 Profit Before Tax 2,898.4 2,875.0 Equity 21,426.9 20,543.1 Adju
Slide 7: Quarter on Quarter Performance
Quarter on Quarter Performance Sustaining a profitable growth trajectory despite cost & supply chain headwinds r----------------------------------- r----------------------------------- 31.9% 3 7 . 0 % 5,618 30.2% 30.2% 5,225 0-.. 28.6% 28.7% ~ ------ j_------- =<, 3 2 . 0 % 5,141 5,093 1 ,5 0 0 -cJ
Slide 8: Financial Performance Track Record
Financial Performance Track Record Robust growth and profitability indicators over the years r------------------------------------ r----------------------------------- 3 5 . 0 % 31.5% 31.4% CAGR 15.3% 18,852 21,232 6 ,0 0 0 5 ,0 0 0 27.6% 30.6% B 29.7% 3 0 . 0 % 15,373 14,050 2 5 . 0 % 12,017 4 ,0 0
Slide 9: Strong Returns Indicators
Strong Returns Indicators ~------------------------------· ROICE ~------------------------------· Fixed Assets Turnover ------------------------ Working Capital Days 40% FY19 FY20 FY21 FY22 H1 FY23 3.3 3.4 3 5 0 2 5 0 202 2.9 176 3 0 0 2.8 173 173 2 0 0 36% 2.7 2 5 0 152 35% 34% 98 1 5 0 114 2 0 0 1
Slide 10: Business Performance Review
02 Business Performance Review 9 G qlenma~k LIFE SCIENCES
Slide 11: Segment Performance – Generic and CDMO business
Segment Performance – Generic and CDMO business 490 5,047 435 4,715 406 Revenue (₹ Mn) 4,590 Revenue (₹ Mn) 4,448 4,533 309 243 Generic API CDMO Q2 FY22 Q3 FY22 Q4 FY22 Q1 FY23 Q2 FY23 Q2 FY22 Q3 FY22 Q4 FY22 Q1 FY23 Q2 FY23 • Generic API revenues in Q2FY23 increased 1 • CDMO revenues in Q2FY23 incr
Slide 12: Segment Performance – GPL vs. External
Segment Performance – GPL vs. External 2177 - 2288 GPL Sales 2150 % of total Revenue 1855 3072 - External Sales 3330 3075 % of total Revenue 3286 3242 3755 74% 41% 41% 41% 1657 66% 64% 36% 1338 59% 59% 59% 34% 26% GPL External Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1F
Slide 13: Market and Therapeutic Area Mix
Market and Therapeutic Area Mix 27% 24% 27% 28% 25% 28% 29% 37% 34% 35% 6% 4% 8% 4% 4% 8% 6% 7% 10% 7% 15% 14% 14% 18% 14% 73% 76% 73% 72% 75% 39% 43% 42% 37% 37% Therapeutic Q2 FY22 Q3 FY22 Q4 FY22 Q1 FY23 Q2 FY23 Market Mix Q2 FY22 Q3 FY22 Q4 FY22 Q1 FY23 Q2 FY23 Area Mix --------------> ■ Regulat
Slide 14: Company Overview
03 Company Overview 13 G qlenma~k LIFE SCIENCES
Slide 15: Global Footprint
Global Footprint Filed 440 DMFs and CEPs across major markets; United States, Europe, Japan, Russia, Brazil, South Korea, Taiwan, Canada, China and Australia ROW 60+ 350+ 30+ 89 104 152 10+ 17 120+ 10+ 50+ 16 62 (Brazil) India – Mix of Regulated Number of Number of customers As of June 30, 2022 Regu
Slide 16: Quality-focused, compliant manufacturing & R&D infrastructure
Quality-focused, compliant manufacturing & R&D infrastructure Manufacturing Infrastructure R&D Infrastructure Annual Installed Capacity (Sept-22) Last USFDA Inspection Date Approvals Mahape, Navi Mumbai USFDA, MHRA (UK), FIMEA R&D for new product development (Finland), Romania (Europe) and complex
Slide 17: R&D Capabilities
R&D Capabilities 6 5 0 572 5 .0 % [______] Cumulative Filing Status ------ 4 .5 % 5 5 0 North 4 .0 % 4 5 0 400 405 Therapy Europe Japan Brazil Australia ROW Total 376 America 3 .5 % 2.7% 3223.2% CVS 36 31 4 16 10 26 123 2.7% 2.6% 3 5 0 3 .0 % 2 5 0 2.1% 2 .5 % CNS 35 19 7 12 1 12 86 2 .0 % Diabetes
Slide 18: Strategy Going Forward
17 04 Strategy Going Forward G qlenma~k 17 LIFE SCIENCES
Slide 19: Strategic Growth Levers
Strategic Growth Levers •New product launches •Ramp up CDMO portfolio •Geographical expansion •Expand into complex API platforms •Focus on new markets becoming •Iron compounds more regulated •Oncology •Pursue 2nd source opportunities with top generic players New Gx API Growth Business levers Operati
Slide 20: Future Capacity Expansion Plan
Future Capacity Expansion Plan Expansion Type Division Location Current Capacity Status & Planned Capacity Operational Timelines 240 KL capacity added in Oct Brownfield API Dahej 141.9 KL - 2022 Under Construction Brownfield Intermediate Ankleshwar 550.2 KL Q3 FY23 400 KL Brownfield Oncology Dahej -
Slide 21: For further information contact
For further information contact Email: complianceofficer@glenmarklifesciences.com Ernst & Young LLP – Investor Relations Diwakar Pingle Email: Diwakar.Pingle@in.ey.com Rahul Thakur Email: rahul.thakur@in.ey.com Mobile: +91 98333 19957 Corporate Office:4th Floor, OIA House, 470, Cardinal Gracious Road,